These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9712273)

  • 1. Development of rifapentine: the way ahead.
    Mitchison DA
    Int J Tuberc Lung Dis; 1998 Aug; 2(8):612-5. PubMed ID: 9712273
    [No Abstract]   [Full Text] [Related]  

  • 2. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong.
    Tam CM; Chan SL; Lam CW; Dickinson JM; Mitchison DA
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):411-6. PubMed ID: 9441094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA approves rifapentine for the treatment of pulmonary tuberculosis.... Food and Drug Administration.
    Roehr B
    J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):19-25. PubMed ID: 11365728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifapentine--a long-acting rifamycin for tuberculosis.
    Med Lett Drugs Ther; 1999 Feb; 41(1047):21-2. PubMed ID: 10076594
    [No Abstract]   [Full Text] [Related]  

  • 5. A lesson to be learned.
    Kanyok T
    Int J Tuberc Lung Dis; 1997 Dec; 1(6):490-2. PubMed ID: 9487444
    [No Abstract]   [Full Text] [Related]  

  • 6. Rifapentine for the treatment of pulmonary tuberculosis.
    Munsiff SS; Kambili C; Ahuja SD
    Clin Infect Dis; 2006 Dec; 43(11):1468-75. PubMed ID: 17083024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed-dose combination formulations for tuberculosis treatment.
    Sbarbaro J; Blomberg B; Chaulet P
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S286-8. PubMed ID: 10593706
    [No Abstract]   [Full Text] [Related]  

  • 8. New approaches to the treatment of latent tuberculosis.
    Sterling TR
    Semin Respir Crit Care Med; 2008 Oct; 29(5):532-41. PubMed ID: 18810686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
    Tam CM; Chan SL; Kam KM; Goodall RL; Mitchison DA
    Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single and multiple dose pharmacokinetics of rifapentine in man: part II.
    Keung A; Eller MG; McKenzie KA; Weir SJ
    Int J Tuberc Lung Dis; 1999 May; 3(5):437-44. PubMed ID: 10331734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Another step on the path to better TB therapies.
    Vernon A; Burman W; Horsburgh CR
    Int J Tuberc Lung Dis; 2002 Jan; 6(1):1-2. PubMed ID: 11931394
    [No Abstract]   [Full Text] [Related]  

  • 12. Doctors report breakthrough antibiotic treatment for TB.
    AIDS Read; 2007 Nov; 17(11):528, 534. PubMed ID: 18167636
    [No Abstract]   [Full Text] [Related]  

  • 13. [Controlled clinical trial on efficacy of 5-month regimens and whole course intermittent 6-month regimens in treating bacillary pulmonary tuberculosis].
    Chu N; Yan B; Zhu L
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jul; 21(7):388-91. PubMed ID: 11326873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assuring bioavailability of fixed-dose combinations of anti-tuberculosis medications. A joint statement of the International Union Against Tuberculosis and Lung Diseases and the World Health Organization.
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S282-3. PubMed ID: 10593704
    [No Abstract]   [Full Text] [Related]  

  • 15. [Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy].
    Aber VR; Nunn AJ
    Bull Int Union Tuberc; 1978 Dec; 53(4):276-80. PubMed ID: 387141
    [No Abstract]   [Full Text] [Related]  

  • 16. Completing tuberculosis prophylaxis in jail: targeting treatment and a comparison of rifampin/pyrazinamide with isoniazid regimens.
    Lambert LA; Ijaz K; Navin TR
    Int J Tuberc Lung Dis; 2005 Feb; 9(2):230; author reply 230-1. PubMed ID: 15732748
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of latent tuberculosis infection.
    Lepage P
    N Engl J Med; 2003 Mar; 348(13):1292-3; author reply 1292-3. PubMed ID: 12661577
    [No Abstract]   [Full Text] [Related]  

  • 18. Proposed minimum registration requirements for fixed-dose combination anti-tuberculosis drugs.
    Fourie PB
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S362-7; discussion S381-7. PubMed ID: 10593719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency.
    Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S322-4; discussion S351-2. PubMed ID: 10593711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberculosis treatment: dangerous regimens?
    Rieder HL; Arnadottir T; Trébucq A; Enarson DA
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):1-3. PubMed ID: 11263509
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.